S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
CGC   18.50 (-3.90%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
T   39.16 (-0.03%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
BAC   32.79 (-0.91%)
DIS   148.72 (+7.32%)
Log in

Pluristem Therapeutics Stock Price, Forecast & Analysis (NASDAQ:PSTI)

$3.27
-0.02 (-0.61 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$3.21
Now: $3.27
$3.40
50-Day Range
$3.26
MA: $3.60
$4.14
52-Week Range
$3.21
Now: $3.27
$11.90
Volume3,425 shs
Average Volume54,736 shs
Market Capitalization$51.38 million
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSTI
CUSIPN/A
Phone972-74-710-7259

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$50,000.00
Book Value$1.43 per share

Profitability

Net Income$-35,310,000.00

Miscellaneous

Employees172
Market Cap$51.38 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive PSTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PSTI and its competitors with MarketBeat's FREE daily newsletter.


Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions

What is Pluristem Therapeutics' stock symbol?

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

When did Pluristem Therapeutics' stock split? How did Pluristem Therapeutics' stock split work?

Shares of Pluristem Therapeutics reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Pluristem Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.10. View Pluristem Therapeutics' Earnings History.

When is Pluristem Therapeutics' next earnings date?

Pluristem Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Pluristem Therapeutics.

What price target have analysts set for PSTI?

3 Wall Street analysts have issued twelve-month target prices for Pluristem Therapeutics' stock. Their forecasts range from $8.00 to $15.50. On average, they expect Pluristem Therapeutics' share price to reach $11.75 in the next year. This suggests a possible upside of 259.3% from the stock's current price. View Analyst Price Targets for Pluristem Therapeutics.

What is the consensus analysts' recommendation for Pluristem Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pluristem Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pluristem Therapeutics.

What are Wall Street analysts saying about Pluristem Therapeutics stock?

Here are some recent quotes from research analysts about Pluristem Therapeutics stock:
  • 1. According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (10/17/2019)
  • 2. Maxim Group analysts commented, "Pluristem provided a shareholder update to highlight upcoming milestones. The company also completed an equity financing on 4/8 raising $21M. We estimate the company has ~$27M in cash on the balance sheet." (4/24/2019)

Has Pluristem Therapeutics been receiving favorable news coverage?

News stories about PSTI stock have been trending very negative on Wednesday, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pluristem Therapeutics earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Pluristem Therapeutics.

Who are some of Pluristem Therapeutics' key competitors?

What other stocks do shareholders of Pluristem Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pluristem Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), Protalix Biotherapeutics (PLX), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), BIOLINERX LTD/S (BLRX), Fate Therapeutics (FATE), ImmunoGen (IMGN), AT&T (T), Gilead Sciences (GILD) and Novavax (NVAX).

Who are Pluristem Therapeutics' key executives?

Pluristem Therapeutics' management team includes the folowing people:
  • Mr. Zami Aberman, Chairman & Co-CEO (Age 65)
  • Mr. Yaky Yanay, Pres, Co-CEO & Director (Age 48)
  • Ms. Chen Franco-Yehuda, CFO, Treasurer & Sec. (Age 35)
  • Mr. Boaz Leshem, VP Operations & Manufacturing (Age 59)
  • Ms. Efrat Kaduri, Director of Bus., Investor and PR

Who are Pluristem Therapeutics' major shareholders?

Pluristem Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (1.39%), Nikko Asset Management Americas Inc. (1.39%) and California Public Employees Retirement System (0.12%). Company insiders that own Pluristem Therapeutics stock include Mark Germain, Moria Kwiat and Yaky Yanay. View Institutional Ownership Trends for Pluristem Therapeutics.

Which major investors are selling Pluristem Therapeutics stock?

PSTI stock was sold by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc. and California Public Employees Retirement System. View Insider Buying and Selling for Pluristem Therapeutics.

How do I buy shares of Pluristem Therapeutics?

Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pluristem Therapeutics' stock price today?

One share of PSTI stock can currently be purchased for approximately $3.27.

How big of a company is Pluristem Therapeutics?

Pluristem Therapeutics has a market capitalization of $51.38 million and generates $50,000.00 in revenue each year. Pluristem Therapeutics employs 172 workers across the globe.View Additional Information About Pluristem Therapeutics.

What is Pluristem Therapeutics' official website?

The official website for Pluristem Therapeutics is http://www.pluristem.com/.

How can I contact Pluristem Therapeutics?

Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 31905. The biotechnology company can be reached via phone at 972-74-710-7259 or via email at http://www.pluristem.com.


MarketBeat Community Rating for Pluristem Therapeutics (NASDAQ PSTI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  320 (Vote Outperform)
Underperform Votes:  236 (Vote Underperform)
Total Votes:  556
MarketBeat's community ratings are surveys of what our community members think about Pluristem Therapeutics and other stocks. Vote "Outperform" if you believe PSTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Featured Article: Investing in Growth Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel